Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-11-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientpatientsdlacuteonset
  Phrases that lowered it: type diabetesmellitusinsulinneurologicalhistory
• Sponsor's past termination rate: 11.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 34 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Disease area, metabolic: Yes (lowers risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke NCT04123067 · started 2020 · scored riskier than 73% of active trials terminated
• REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) NCT00640991 · started 2008 · scored riskier than 60% of active trials completed
• Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke NCT02054429 · started 2013 · scored riskier than 94% of active trials completed
• Neuroprotection of Pioglitazone in Acute Ischemic Stroke NCT02195791 · started 2014 · scored riskier than 20% of active trials terminated
• Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction NCT00670228 · started 2008 · scored riskier than 22% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.